BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 38342826)

  • 1. Diffuse Midline H3K27-Altered Gliomas in the Spinal Cord: A Systematic Review.
    Watanabe G; Wong JM; Estes B; Khan MF; Ogasawara C; Umana GE; Martin AR; Bloch O; Palmisciano P
    J Neurooncol; 2024 Feb; 166(3):379-394. PubMed ID: 38342826
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of adjuvant chemotherapy in patients with H3K27 altered diffuse midline gliomas: a multicentric retrospective study.
    Di Nunno V; Lombardi G; Simonelli M; Minniti G; Mastronuzzi A; Di Ruscio V; Corrà M; Padovan M; Maccari M; Caccese M; Simonetti G; Berlendis A; Farinotti M; Pollo B; Antonelli M; Di Muzio A; Dipasquale A; Asioli S; De Biase D; Tosoni A; Silvani A; Franceschi E
    J Neurooncol; 2024 Mar; 167(1):145-154. PubMed ID: 38457090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pediatric diffuse midline glioma H3K27- altered: A complex clinical and biological landscape behind a neatly defined tumor type.
    Vallero SG; Bertero L; Morana G; Sciortino P; Bertin D; Mussano A; Ricci FS; Peretta P; Fagioli F
    Front Oncol; 2022; 12():1082062. PubMed ID: 36727064
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinicopathological characteristics and prognosis of diffuse midline gliomas with histone H3K27M mutation: an analysis of 30 cases].
    Li HN; Shan CG; Fan CZ; Cheng LN; Wu SG; Liu MT; Jiang GY; Li Z
    Zhonghua Bing Li Xue Za Zhi; 2019 Mar; 48(3):192-198. PubMed ID: 30831644
    [No Abstract]   [Full Text] [Related]  

  • 5. Adult diffuse midline gliomas: Clinical, radiological, and genetic characteristics.
    Dono A; Takayasu T; Ballester LY; Esquenazi Y
    J Clin Neurosci; 2020 Dec; 82(Pt A):1-8. PubMed ID: 33317715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Case Report: Five Adult Cases of H3K27-Altered Diffuse Midline Glioma in the Spinal Cord.
    Gu Q; Huang Y; Zhang H; Jiang B
    Front Oncol; 2021; 11():701113. PubMed ID: 34956856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinicopathological characteristics of H3K27-altered diffuse midline glioma and evaluation of NTRK as its therapeutic target].
    Duan ZJ; Feng J; Yao K; Hu ZJ; Ma Z; Xiang L; Zhang XF; Qi XL
    Zhonghua Bing Li Xue Za Zhi; 2022 Nov; 51(11):1115-1122. PubMed ID: 36323540
    [No Abstract]   [Full Text] [Related]  

  • 8. Spinal Cord Diffuse Midline Gliomas With H3 K27m-Mutant: Clinicopathological Features and Prognosis.
    Wang YZ; Zhang YW; Liu WH; Chai RC; Cao R; Wang B; An SY; Jiang WJ; Xu YL; Yang J; Jia WQ
    Neurosurgery; 2021 Jul; 89(2):300-307. PubMed ID: 34015818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transcriptomic and epigenetic profiling of 'diffuse midline gliomas, H3 K27M-mutant' discriminate two subgroups based on the type of histone H3 mutated and not supratentorial or infratentorial location.
    Castel D; Philippe C; Kergrohen T; Sill M; Merlevede J; Barret E; Puget S; Sainte-Rose C; Kramm CM; Jones C; Varlet P; Pfister SM; Grill J; Jones DTW; Debily MA
    Acta Neuropathol Commun; 2018 Nov; 6(1):117. PubMed ID: 30396367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MRI and Molecular Characterization of Pediatric High-Grade Midline Thalamic Gliomas: The HERBY Phase II Trial.
    Rodriguez D; Calmon R; Aliaga ES; Warren D; Warmuth-Metz M; Jones C; Mackay A; Varlet P; Le Deley MC; Hargrave D; Cañete A; Massimino M; Azizi AA; Saran F; Zahlmann G; Garcia J; Vassal G; Grill J; Peet A; Dineen RA; Morgan PS; Jaspan T
    Radiology; 2022 Jul; 304(1):174-182. PubMed ID: 35412366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pediatric spinal cord diffuse midline glioma, H3 K27-altered with intracranial and spinal leptomeningeal spread: A case report.
    Serrallach BL; Tran BH; Bauer DF; Mohila CA; Adesina AM; McGovern SL; Lindsay HB; Huisman TA
    Neuroradiol J; 2022 Oct; 35(5):634-639. PubMed ID: 34989626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dynamic susceptibility contrast-MRI parameters, ADC values, and the T2-FLAIR mismatch sign are useful to differentiate between H3-mutant and H3-wild-type high-grade midline glioma.
    Kurokawa R; Kurokawa M; Baba A; Ota Y; Kim J; Capizzano A; Srinivasan A; Moritani T
    Eur Radiol; 2022 Jun; 32(6):3672-3682. PubMed ID: 35022811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adult diffuse midline gliomas H3 K27-altered: review of a redefined entity.
    López-Pérez CA; Franco-Mojica X; Villanueva-Gaona R; Díaz-Alba A; Rodríguez-Florido MA; Navarro VG
    J Neurooncol; 2022 Jul; 158(3):369-378. PubMed ID: 35567713
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spinal Cord Diffuse Midline Glioma With Histone H3 K27M Mutation in a Pediatric Patient.
    Cheng R; Li DP; Zhang N; Zhang JY; Zhang D; Liu TT; Yang J; Ge M
    Front Surg; 2021; 8():616334. PubMed ID: 34222313
    [No Abstract]   [Full Text] [Related]  

  • 15. Distinct MRI characteristics of spinal cord diffuse midline glioma, H3 K27-altered in comparison to spinal cord glioma without H3 K27-alteration and demyelination disorder.
    Ying Y; Liu X; Li X; Mei N; Ruan Z; Lu Y; Yin B
    Acta Radiol; 2024 Mar; 65(3):284-293. PubMed ID: 38115811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comprehensive genomic study of 390 H3F3A-mutant pediatric and adult diffuse high-grade gliomas, CNS WHO grade 4.
    Williams EA; Brastianos PK; Wakimoto H; Zolal A; Filbin MG; Cahill DP; Santagata S; Juratli TA
    Acta Neuropathol; 2023 Sep; 146(3):515-525. PubMed ID: 37524847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new subtype of diffuse midline glioma, H3 K27 and BRAF/FGFR1 co-altered: a clinico-radiological and histomolecular characterisation.
    Auffret L; Ajlil Y; Tauziède-Espariat A; Kergrohen T; Puiseux C; Riffaud L; Blouin P; Bertozzi AI; Leblond P; Blomgren K; Froelich S; Picca A; Touat M; Sanson M; Beccaria K; Blauwblomme T; Dangouloff-Ros V; Boddaert N; Varlet P; Debily MA; Grill J; Castel D
    Acta Neuropathol; 2023 Dec; 147(1):2. PubMed ID: 38066305
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Panobinostat in adults with H3 K27M-mutant diffuse midline glioma: a single-center experience.
    Neth BJ; Balakrishnan SN; Carabenciov ID; Uhm JH; Daniels DJ; Kizilbash SH; Ruff MW
    J Neurooncol; 2022 Mar; 157(1):91-100. PubMed ID: 35076860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Diffuse midline glioma with H3K27 alteration in adults: a clinicopathological analysis].
    Yang QY; Li MN; Chen TY; Liu C; Li X; Shi ZM; Pan MH
    Zhonghua Bing Li Xue Za Zhi; 2023 Apr; 52(4):376-383. PubMed ID: 36973199
    [No Abstract]   [Full Text] [Related]  

  • 20. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
    Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
    Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.